Sixty patients with endoscopically confirmed gastric ulceration took part in a single-blind trial of cimetidine 1 g daily compared with conventional treatmentnamely, carbenoxolone in patients aged under 60 and Caved-(S) in those over 60.
choice in gastric ulceration ? and Is maintenance treatment needed once ulcer healing has been achieved ? We have conducted a trial comparing cimetidine with conventional medical treatment-namely, carbenoxolone for patients aged under 60 and Caved-(S) for the over-60s. Treatment was continued for up to three months or until healing occurred if sooner. The patients were completely unsclected, and in some 400, of cases the ulcer was first diagnosed after hospital admission for gastrointestinal bleeding. Once ulcer healing was achieved treatment was stopped and the patient carefully followed up for evidence of recurrence.
Patients and methods
The study was performed concurrently at two hospitals using identical protocols and in accordance with the Declaration of Helsinki. The nature of the trial was fully explained to the patients before entry and their informed consent obtained.
Drutg treatmient anld dosage-All patients with proved gastric ulceration who were suitable for medical care were allocated at random to one of four treatment groups according to a code held and administered solely by the pharmacy. Thus we did not know which treatment the patients were receiving. Those under 60 were given either cimetidine, 200 mg three times a day and 400 mg at night, or carbenoxolone, at an initial dose of 100 mg thrice daily for one week but then reduced to 50 mg thrice daily. Patients over 60 received either cimetidine (1 g daily) or Caved-(S), two tablets three times a day between meals. All patients were given antacids (Rennies) to take as required. They received no specific dietary advice but were discouraged from smoking. A personal diary card was completed daily recording severity of symptoms, number of antacids taken, and drug compliance. Treatment was given for up to three months but stopped when healing occurred.
Initial investigations and follozc-ip-Endoscopy was performed in all cases before patients entered the trial to exclude malignancy. The sizc and site of ulcers were usually assessed radiologically ulcers were defined as small (cross-sectional area less than 50 mm7), medium (50-200 mm2), and largc (over 200 mm2). The patients were followed up monthly with either a barium meal or endoscopy. Ulcer 
Results
Between January 1976 and February 1978, 67 patients entered the trial. Seven were subsequently withdrawn. Two were found on biopsy to have unsuspected gastric cancer; three underwent surgery, two for continuing gastrointestinal bleeding and one for an incarcerated hiatus hernia with obstruction; one died from a cerebrovascular accident; and one was withdrawn owing to a generalised rash during treatment with cimetidine. The remaining 60 patients form the basis of this report. TREATMENT 
GROUPS
The four treatment groups were evenly matched for age (table I). There was some variation in sex ratio, but this was not significant. Most of the under-60s were smokers, whereas only half of the over60s smoked (P < 0-001).
Twenty-eight patients had their gastric ulcer diagnosed after emergency admission to hospital, 25 because of acute gastrointestinal bleeding and three because of initially undiagnosed abdominal or chest pain (table II) . The ratio of inpatients to outpatients was similar in all four treatment groups, as was the average number of trial days spent in hospital. There was no appreciable difference between the groups in the distribution of initial ulcer size (table III) .
ULCER HEALING
After two and seven weeks of treatment two patients in the carbenoxolone group were withdrawn because of uncontrolled dyspepsia. A further three had ulcers that remained unhealed after three months (table IV). In the under-60s cimetidine group all nine patients had 
RELIEF OF SYMPTOMS
Analysis of the diary cards showed only minor differences between the four groups in the relief of symptoms.
Uiider-60s-Patients in both treatment groups entered the trial with similar degrees of dyspepsia (day and night pain) and showed no appreciable difference in their rather slow response to treatment.
Over-60s-The pretreatment severity of daytime dyspepsia was similar in the two treatment groups. There was a trend in favour of Caved-(S) from the third week, which just reached significance by the fourth week (P < 0-05). Patients in the Caved-(S) group had less night painl before treatment (P < 0-05), and their response to treatment was similar to that in the cimetidine group until the third week, when once again a response in favour of Caved-(S) just reached significance (P < 0 05). figure. No asymptomatic recurrences were found on routine radiography.
Factors affecting recurrence
Initial inpatient treatment was the only factor found to affect ulcer recurrence; there were only three recurrences among the 25 inpatients compared with 13 among the 29 patients treated wholly as outpatients (Fisher's exact test: P <005).
Factors not affecting recurrenice Speed of ulcer healing-Twenty-five ulcers healed with one month of treatment, and nine recurred. Twenty-three ulcers healed with two months of treatment, and five recurred. Six ulcers took three months to heal, and two recurred.
Initial ulcer size-Of the 12 small ulcers, six recurred; of the 29 medium-sized ulcers, nine recurred; and of the 13 large ulcers one recurred.
Ulcer site-Sixteen patients had ulcers in the antrum, and there were five recurrences; 24 had mid-body ulcers, and seven recurred; and 14 had upper-body ulcers, and four recurred.
Treatment grolup-Ulcers recurred in all treatment groups (table V)-in three out of seven patients given carbenoxolone, eight out of 29 given cimetidine, and five out of 18 given Caved-(S).
Sex-There were nine ulcer recurrences among the 27 men, and seven among the 27 women.
Age-Recurrence occurred in five of the 16 patients aged under 60, and I1 of the 38 aged over 60.
Smoking-Of the 33 smokers, 10 had recurrences; and of the 21 non-smokers, six had recurrences.
Previous history-Of the 16 patients with ulcer recurrences, nine had a previous history of peptic ulceration. Such a history was present in only 12 of the 38 who had not had a recurrence.
Acid secretioni studies-Pentagastrin studies on 11 out of the 16 patients with ulcer recurrence showed a nearly normal scatter (mean basal acid output 6-3 mmol (mEq),h (range 0-1-27 3), total acid output 17 9 mmol, h (0 5-30 2), and maximum acid output 32-4 mmol/h (1 0-39 6). Previous studies of cimctidine have aimed to assess its healing effect on gastric ulceration. Treatment periods have usually bcen short (four to six weeks) and healing rates have been between 69" and 79"o. What is not known is whether a 100", healing rate would have been achieved if treatment had been continued for three months. We have tried to answer this by assessing ulcer healing at monthly intervals and defining failure as nonhealing after three months of continuous treatment. Endoscopy was performed at the start of the study to exclude cancer, as in a Veterans Administration co-operative study10 one in 25 patients thought to have a benign ulcer turned out to have an underlying carcinoma. We used radiography for follow-up, since this permitted an easier assessment of ulcer size. Healing, however, was always checked by endoscopy, and the end-point of the study was complete epithelial regeneration at the ulcer base.
In our study cimetidine was accompanied by gastric ulcer healing. Among the 29 patients treated a healing rate of 410' (12 cases) was achieved at one month, rising to 90'0 (26) at two months and 100", atthree months. One patient developed a drug eruption necessitating his withdrawal from the trial. Otherwise side effects were minimal, and results of laboratory safety tests were all essentially normal. In the patients under 60 cimetidine was slightly more successful in producing ulcer healing than carbenoxolone (P=0 039). Owing to the small number of patients in this subgroup (21) the clinical validity of this is uncertain. Nevertheless, cimetidine appears to have fewer serious side effects than carbenoxolone, and so may ultimately replace it for the treatment of gastric ulceration.
In patients over 60 there was no appreciable difference in gastric ulcer healing rates between the Caved-(S)-treated and cimetidine-treated groups. Caved-(S) used in the dosage employed in this study, however, is only a quarter of the price of cimetidine, and may have fewer side effects. We cannot comment on the use of Caved-(S) in patients under 60 but would expect similar results.
During follow-up some 3000 of the healed gastric ulcers recurred within 18 months irrespective of the treatment regimen. In the Veterans Administration co-operative study 4200 of ulcers that had originally healed recurred within two years."' Similarly Piper et al in a four-year study" found a recurrence rate of 26',, in patients discharged from hospital with healed ulcers compared with 6100 in patients discharged before ulcer healing. In our study the only factor that appeared to influence the recurrence rate was a period of initial inpatient treatment, which, although it did not speed ulcer healing, apparently reduced the incidence of recurrence (from 450% to 12"0).
From this and other studies it seems that medical treatment will heal most gastric ulcers. The problem that remains is to prevent their recurrence.'2 Some two-thirds of our patients were over 60 and were not ideal for gastric surgery. An effective maintenance treatment is therefore needed, and two studies have suggested cimetidine.'4 15 Preliminary results of our two-year follow-up study suggest that all future studies on gastric ulcer treatment should include maintenance therapy.
Introduction
Studies on patients with rheumatoid arthritis (RA) have shown no consistent substantial association between the disease and any HILA-A-locus or B-locus antigens'--but a highly significant association between RA and DW4. 6 RA is associated with extra-articular manifestations such as nodules, cutaneous vasculitis, peripheral neuropathy, Sjogren's syndrome, and fibrosing alveolitis. During treatment with drugs, especially gold compounds and penicillamine, toxic reactions may occur. These include rashes, proteinuria, and reduced numbers of circulating leucocytes and platelets. Some of these toxic reactions and the extra-articular manifestations may be mediated immunologically.13-II We decided to re-examine the association between erosive RA and the DR antigens and investigate the possible relation between HLA antigens and extra-articular manifestations of the disease and toxic reactions to sodium aurothiomalate and penicillamine.
Subjects and methods
Ninety-five Caucasian patients with classical or definite rheumatoid arthritis according to the ARA criteria' were studied. Except for thesc ethnic and clinical criteria no selection was made. The group comprised 63 women and 32 men aged 29-76 years. We looked for extraarticular manifestations both at the time of the study and retrospectively in the case notes. This disclosed 39 patients with rheumatoid nodules, five with vasculitis, nine with rheumatoid lung, and two with peripheral neuropathy. A few patients had other clinical complications, nine having Sjogren's syndrome and one Felty's syndrome.
A total of 59 patients had been given courses of either sodium aurothiomalate (50 mg monthly) or penicillamine (up to 1200 mg daily) or both. Thirty had received only sodium aurothiomalate, 23 sodium aurothiomalate and penicillamine, and six only penicillamine. Toxic reactions were monitored by periodic urine analyses, blood counts, and physical examination. Since toxic reactions are particularly common during the first six months of treatment, patients had to be free of symptoms of toxicity for at least this period of treatment to be scored as drug-reaction negative.
Direct questioning was used to elicit a family history of RA and the agc at onset of the disease.
IMMUNOLOGICAL TESTS
The highest recorded differential agglutination titre for rheumatoid factor as detected by the sensitised sheep red blood cell technique of Rose-Waaler was noted. This test was performed in several routine laboratories on widely separated occasions, however, so we decided to
